株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

新興市場における医薬品企業・保険者間の提携

Pharma-Payer Partnerships in Emerging Markets

発行 Datamonitor Healthcare 商品コード 570533
出版日 ページ情報 英文 72 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.93円で換算しております。
Back to Top
新興市場における医薬品企業・保険者間の提携 Pharma-Payer Partnerships in Emerging Markets
出版日: 2017年08月14日 ページ情報: 英文 72 Pages
概要

当レポートでは、新興市場における医薬品企業・保険者間の提携環境について調査し、保険者との提携のメリット、各種提携オプション、医療費自己負担市場および償還制度のある市場における提携の分析、重要成功因子の分析などをまとめています。

エグゼクティブサマリー

  • 保険者との提携:新興市場におけるアクセスを推進
  • 保険者との提携:資金源により多くの形態が存在
  • カスタム化:医療費自己負担市場において提携成功の鍵
  • 償還制度のある新興市場においても成果払いは稀
  • もっとも有効な提携:ローカルレベルの推進によるもの

医薬品企業・保険者の提携環境

  • 保険者との提携新興市場での市場機会を開放
  • 市場構造が提携を形成
  • 文献

医療費自己負担の新興市場における提携

  • 医療費自己負担市場:提携オプションのサマリー
  • 義援による提携
  • 階層化による薬価設定
  • 継続的治療プログラム
  • 補足的健康保険
  • 文献

償還制度のある新興市場における提携

  • サービス支援がアクセスを推進
  • 勢いを増すリアルワールドエビデンス
  • リスク共有
  • 技術移転
  • 文献

重要成功因子

  • 提携と地域目標との連携
  • 各種提携オプションにおけるリスク/リワードの分析

付録

目次
Product Code: DMKC0176385

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include "strategic philanthropy," patient access programs, tiered pricing, and service support models. Many of the most successful strategies are hybrids of two or more "pure" partnership archetypes.

This analysis is a survey of recent industry experience with payer partnerships in emerging markets, using case studies and real-world exemplars to illustrate best practice. While there is no "one size fits all" approach to partnering in emerging markets, Datamonitor Healthcare has considered in each case how best to address payer needs that cannot be served by the routine course of business.

This analysis covers self-pay markets, partially reimbursed, and reimbursed emerging markets. Pharmaceutical companies that can overcome payer resistance, and take a proactive approach, can reap significant rewards from innovative partnerships in challenging, high-growth markets.

TABLE OF CONTENTS

5. EXECUTIVE SUMMARY

  • Partnerships with payers facilitate access in emerging markets
  • Partnerships with payers take many forms, depending on funding source
  • Customization is key for successful partnerships in self-pay markets
  • Even in reimbursed emerging markets, paying for outcomes is rare
  • The most successful partnerships are driven at the local level

7. THE PHARMA-PAYER PARTNERSHIPS LANDSCAPE

  • Payer partnerships are unlocking emerging-market opportunities
  • The market structure shapes the partnership
  • Bibliography

12. PARTNERSHIPS IN SELF-PAY EMERGING MARKETS

  • Self-pay markets: summary of partnership options
  • Donation partnerships
  • Tiered pricing
  • Continuous treatment programs
  • Complementary health insurance
  • Bibliography

41. PARTNERSHIPS IN REIMBURSED EMERGING MARKETS

  • Service support can boost access in reimbursed markets
  • Real-world evidence is gaining traction in emerging markets
  • Risk sharing in reimbursed emerging markets
  • Technology transfer in emerging markets
  • Bibliography

65. CRITICAL SUCCESS FACTORS FOR PARTNERSHIPS IN EMERGING MARKETS

  • Aligning partnerships with local goals and capabilities is key
  • Assessing risk-reward in partnering options

70. APPENDIX

  • About the author
  • Methodology

LIST OF FIGURES

  • Figure 1: Payer partnership options in emerging markets
  • Figure 2: Donation/tiered pricing archetype
  • Figure 3: Novartis access differentiated strategy
  • Figure 4: Continuous treatment program archetype
  • Figure 5: Discount card archetype (variant of CTP model)
  • Figure 6: Complementary insurance partnership archetype
  • Figure 7: Stakeholder map of Turkey
  • Figure 8: Outcomes-based risk sharing archetype
  • Figure 9: Stakeholder map of Mexico
  • Figure 10: Technology transfer archetype (Brazilian Partnerships for Productive Development model)
  • Figure 11: Requirements for emerging-market payer partnerships

LIST OF TABLES

  • Table 1: Risk-benefit matrix: partnerships in self-pay markets
  • Table 2: Case study 1: The Max Foundation
  • Table 3: Case study 2: Novartis Philippines and Roche Egypt
  • Table 4: Case study 3: Sanofi's emerging-market partnerships
  • Table 5: Case study 4: PAPs in Argentina
  • Table 6: Case study 5: Complementary insurance programs in China
  • Table 7: Case study 6: Payer support programs in Latin America
  • Table 8: Case study 7: Risk sharing in three Latin American markets
  • Table 9: Case study 8: Technology transfer programs in Brazil
  • Table 10: Options for payer partnerships by market archetype
Back to Top